hsa_circ_0115355 promotes pancreatic β-cell function in patients with type 2 diabetes through the miR-145/SIRT1 axis

J Clin Lab Anal. 2022 Jul 2;e24583. doi: 10.1002/jcla.24583. Online ahead of print.

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a complex metabolic disease closely related to obesity, a growing global health problem. T2DM is characterized by decreased islet beta-cell mass and impaired insulin release from these cells, and this dysfunction is exacerbated by hyperglycemia (glucolipotoxicity). Circular RNAs (circRNAs) are abnormally expressed and play a regulatory role in T2DM.

Objective: This study aimed to evaluate the function and molecular mechanism of hsa_circ_0115355 in the progression of T2DM.

Methods: The regulatory effect of hsa_circ_0115355 on INS-1 cell function was assessed under glucolipotoxicity by MTT, flow cytometry analysis, and insulin secretion assay. Dual-luciferase experiments revealed a direct interaction of hsa_circ_0115355 with miR-145 and miR-145 with SIRT1. Furthermore, the regulatory role of the hsa_circ_0115355/miR-145/SIRT1 axis was verified by examining the function of INS-1.

Results: In this study, hsa_circ_0115355 was significantly underexpressed in both patients with T2DM and INS-1 cell lines. This study thus showed that hsa_circ_0115355 inhibits the occurrence and development of T2DM by regulating the expression of SIRT1 by adsorbing miR-145.

Conclusion: The underexpression hsa_circ_0115355 is also a potential novel diagnostic marker and therapeutic target for T2DM.

Keywords: INS-1; SIRT1; T2DM; hsa_circ_0115355.